NEWS
The information contained in each news post on this page was factually accurate on the date it was issued and posted.
40th Annual J.P. Morgan Heathcare Conference – Presentation
Webcast, Jan 13, 2022 at 11:15AM EST
Sutro Biopharma to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 6, 2022– Sutro Biopharma, Inc. (“Sutro” or the “Company”) (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create...
Virtual KOL Event: Discussion of STRO-002 Interim Dose Expansion Cohort Data – Presentation
Webcast, Jan 5, 2022 at 5:00pm EST
Sutro Biopharma Announces Interim Data from Dose-Expansion Cohort of STRO-002 Phase 1 Study for Patients with Advanced Ovarian Cancer
- 33% Objective Response Rate (ORR) was observed in 33 RECIST evaluable patients across all FolRα expression levels and both dose levels. - Dose response was observed, with a 47% ORR in 17 patients who started at the 5.2 mg/kg dose level. - Tumor proportion score...
Sutro Biopharma Announces Company KOL Virtual Event to Provide Interim Dose Expansion Data for Antibody-Drug Conjugate Program STRO-002 for Treatment of Advanced Ovarian Cancer
- Dr. Naumann and Sutro management to discuss interim data on the STRO-002 Phase 1 dose-expansion cohort at Company event scheduled for Wednesday, Jan. 5, 2022 at 5 pm ET, or 2 pm PT SOUTH SAN FRANCISCO, Calif., Dec. 27, 2021 – Sutro Biopharma, Inc. (“Sutro”),...
Sutro Biopharma and Tasly Biopharmaceuticals Enter into Exclusive License Agreement for STRO-002 in Greater China
- Tasly obtains exclusive development and commercialization rights for STRO-002 for Greater China - - License includes a $40 million upfront payment to Sutro, and potentially up to $345 million in development and commercial milestone payments - - Partnership builds on...
Fred Hutchinson Cancer Research Center, in Partnership with Sutro Biopharma, to Present at ASH 2021
– Nonclinical data for STRO-002 and STRO-001 are shared in two oral presentations at the 63rd American Society of Hematology Annual Meeting SOUTH SAN FRANCISCO, Calif, Dec. 13, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development...
4th Annual Evercore ISI HeathCONx Conference – Presentation
Webcast, Nov 30, 2021 at 10:05am EST Download Presentation, Click Here
Piper Sandler 33rd Annual Healthcare Conference – Presentation
Webcast, Nov 22, 2021 at 10:00am EST Download Presentation, Click here
Sutro Biopharma to Participate in Two Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Nov. 22, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...